Search Results

Presage Biosciences has entered into an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company.

Presage Biosciences, a biotechnology company whose mission is to enable precision drug response evaluation in the human tumor microenvironment (TME), announced that the U.S. Food and Drug Administration (FDA) has issued a Study May Proceed notification for testing a pre-GMP drug candidate with the CIVO® platform.

Presage Biosciences will present at the Immunology, TME Minisymposium at the American Association for Cancer Research (AACR) 2023 Annual Meeting.

Presage Biosciences, a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, today announced it has entered into a new research collaboration with Poland-based biopharmaceutical company Pure Biologics to evaluate two of Pure Biologics’ very early stage assets in a Phase 0 intratumoral microdosing study.

Presage Biosciences, a biotechnology company whose mission is understanding the complexity of drug response in the tumor microenvironment, today announced completion of a first-of-its-kind Phase 0 clinical study utilizing its CIVO® (Comparative In Vivo Oncology) multiplexed microdosing technology.

Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the second half of 2026.